Shilpa Medicare Limited
NSE: SHILPAMEDMarket Closed • NSE
Day range
52 week range
Shilpa Medicare Limited closed at INR1021.70 (-0.35%) on volume 0.48x its 20-day average, trading 6.69% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -6.5% QoQ
2026-09-04
DIVIDEND Announced
Dividend - Re 0.60 Per Share
2025-10-03
BONUS Announced
Bonus 1:1
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.25x
High Cash Flow Conversion: CFO/PAT averaged 1.41x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 72.2x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 04 Sept 2026 | Dividend | ₹0.60 / share | — | 04 Sept 2026 |
| 03 Oct 2025 | Bonus issue | 1:1 bonus ratio | — | 03 Oct 2025 |
| 17 Sept 2025 | Dividend | ₹1.00 / share | — | 17 Sept 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 22 Sept 2023 |
| — | Dividend | ₹1.10 / share | — | 19 Sept 2022 |
| 21 Sept 2021 | Dividend | ₹1.10 / share | — | 20 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2021 |
| 17 Mar 2020 | Dividend | ₹1.10 / share | — | 16 Mar 2020 |
| — | Dividend | ₹1.00 / share | — | 12 Sept 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Sept 2018 |
| 05 Mar 2018 | Dividend | ₹0.70 / share | — | 01 Mar 2018 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Sept 2017 |
| 22 Mar 2017 | Dividend | ₹0.60 / share | — | 21 Mar 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 20 Sept 2016 |
| 29 Mar 2016 | Dividend | ₹0.60 / share | — | 28 Mar 2016 |
| 09 Nov 2015 | Dividend | ₹2.00 / share | — | 06 Nov 2015 |
| — | Dividend | ₹1.10 / share | — | 16 Sept 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.[1]
IndiaHealthcare
Is Shilpa Medicare Limited Shariah compliant?
Shilpa Medicare Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (3.3%) complies with AAOIFI threshold (≤ 33%).
What is Shilpa Medicare Limited's current valuation relative to peers?
Shilpa Medicare Limited trades at a P/E of 72.2x compared to the sector median of 37.6x, and a Price-to-Book of 7.7x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.25x. Interest coverage is 3.1x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 3.6% while net profit growth averaged 25.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.